Beximco Pharmaceuticals Limited

Equities

BXPHARMA

BD0453BXPH04

Pharmaceuticals

End-of-day quote Dhaka S.E. 07:00:00 2024-03-27 pm EDT 5-day change 1st Jan Change
114.6 BDT +0.17% Intraday chart for Beximco Pharmaceuticals Limited -2.22% -21.61%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Beximco names Iqbal Ahmed as managing director AN
Beximco Pharmaceuticals to strengthen portfolio as interim profit up AN
Beximco Pharmaceuticals Limited Reports Earnings Results for the Second Quarter and Six Months Ended December 30, 2023 CI
Beximco Pharmaceuticals Limited Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023 CI
Beximco MD steps down to join Bangladeshi cabinet AN
Beximco Pharmaceuticals Limited Announces Stepping Down of Mr. Nazmul Hassan as Member of the Board CI
Beximco Pharmaceuticals Limited Announces Stepping Down of Mr. Nazmul Hassan as Managing Director CI
Beximco Pharmaceuticals Posts Higher Fiscal Q1 Profit, Revenue MT
Beximco Pharmaceuticals Limited Reports Earnings Results for the First Quarter Ended September 30, 2023 CI
Beximco boosts revenue in local currency but profit falls AN
Beximco Pharmaceuticals Limited Reports Earnings Results for the Full Year Ended June 30, 2023 CI
Beximco Pharmaceuticals Limited Proposes Dividend for the Year Ended June 30, 2023 CI
Beximco working to fix deficiencies at manufacturing plant AN
Beximco Pharmaceuticals to Tackle Ophthalmic Manufacturing Unit Deficiencies After Malta Medicines Authority Audit MT
EARNINGS UPDATES: HC Slingsby profit falls, East Imperial loss narrows AN
Beximco Pharmaceuticals Limited Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2023 CI
TRADING UPDATES: Ferro-Alloy eyes revenue to drop below market view AN
Beximco Pharmaceuticals Limited Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2022 CI
Beximco Pharmaceuticals Limited Announces Cash Dividend for the Year Ended June 30, 2022 CI
UK shareholder meetings calendar - next 7 days AN
EARNINGS SUMMARY: Goodbody shifts away from Covid; Beximco profit down AN
Beximco Pharmaceuticals Limited Reports Earnings Results for the First Quarter Ended September 30, 2022 CI
IN BRIEF: Beximco Pharmaceuticals revenue up thanks to domestic sales AN
Beximco Pharmaceuticals Limited Reports Earnings Results for the Full Year Ended June 30, 2022 CI
UK earnings, trading statements calendar - next 7 days AN
Chart Beximco Pharmaceuticals Limited
More charts
Beximco Pharmaceuticals Ltd. is a manufacturer and exporter of medicines in Bangladesh. The Company is engaged in manufacturing and marketing of generic pharmaceuticals formulation products covering a range of therapeutic categories. It offers products in different dosage forms including solid, liquid, cream and ointment, suppositories, metered dose inhaler, dry powder inhaler, nasal spray, sterile, lyophilized injectable and large volume intravenous fluids. It also manufactures active pharmaceutical ingredients (APIs) and renders contract manufacturing services to other companies. It produces different presentations, and the portfolio encompasses all key therapeutic categories, including antibiotics, analgesics, anti-diabetic, respiratory, cardiovascular, central nervous system, dermatology, gastrointestinal and others. The Company's products include Atrizin, Nomos, Azithrocin, Ceftoril, Bemsivir, Viraflu, Viracin, Rilovir, Flurium, Nervalin, Seropam, Nightus, and others.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
114.6 BDT
Average target price
153.5 BDT
Spread / Average Target
+33.94%
Consensus

Annual profits - Rate of surprise

  1. Stock
  2. Equities
  3. Stock Beximco Pharmaceuticals Limited - Dhaka S.E.
  4. News Beximco Pharmaceuticals Limited
  5. Beximco Jumps 6% on License to Produce Merck & Co.'s COVID-19 Drug in Bangladesh